ADMA Biologics, Inc. (ADMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.62+0.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Net income improves to at least $45 million in Q1 2026: Net income $45.3M vs $45M target.
ADMA Biologics grows revenue to about $545 million in 2026. Profitability improves with net income rising to $45 million in Q1 2026. Cash from operations turned positive to $58 million in Q1 2026. FDA label expansion supports future revenue growth.
Revenue growth is stagnant, with Q1 2026 revenue flat at $114.5 million. Earnings missed estimates recently, showing fragile execution. Cash flow improvements may not sustain if sales do not grow.
The market prices in about 24% revenue growth and values the stock roughly 36% below our fair value of $14.21. Our fair value is 32% below the Street median, reflecting cautious optimism versus peers.
Breaks if: Cash from operations falls below $58 million in Q1 2026
Breaks if: Net income falls below $45 million in Q1 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis is intact, supported by strong recent financial performance and management's focus on disciplined capital allocation.
The market currently prices ADMA as cheap compared to its peers, with a notable expectations gap. This suggests that while some risks are acknowledged, there is room for positive surprises if management executes well.
Fundamentals are likely to remain stable, given management's focus on driving revenue growth and advancing the SG-001 development program. However, there is a near-term risk of missing earnings expectations, particularly as industry peers have faced challenges.
The thesis hinges on management's ability to maintain guidance and deliver on growth initiatives. Additionally, broader sector performance and economic conditions, such as job growth, will influence ADMA's trajectory.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the thesis. However, a rating downgrade raises concerns about potential revenue growth.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Aim to enhance profitability through operational efficiencies and strategic initiatives.
Breaks if: Loss or reversal of FDA label expansion benefits
Focus on increasing total revenue through strategic initiatives.
Breaks if: Revenue falls below $530 million in FY 2026
Focus on increasing total revenue through strategic initiatives.
In summary, ADMA presents a stable investment opportunity with potential upside if management executes effectively and sector conditions remain favorable. Not investment advice.